Cannabis
PurMinds NeuroPharma to Present at Psychedelic Capital: Jan 2022 by Microdose on Thursday, January 27
Toronto, Ontario–(Newsfile Corp. – January 27, 2022) – PurMinds NeuroPharma, a Canadian neuroscience company pursuing breakthrough solutions for devastating neurological disorders with a special emphasis on neurodegenerative diseases, will be presenting at Psychedelic Capital: Jan 2022 by Microdose on Thursday, January 27.
Get Free Tickets Here: https://microdose.buzz/PURMINDS
The coupon code PURMINDS will also work upon checkout.
Date & Time of the Event: 01/27/2022 01:30pm EST
Date & Time of Their Panel: 01/27/2022 03:15pm EST
While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders.
What is Psychedelic Capital: Jan 2022?
Psychedelic Capital covers the top companies, latest IPOs, newest opportunities & deepest insights in the psychedelic industry.
For more information, please visit: https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-jan-2022/
About PurMinds NeuroPharma
PurMinds NeuroPharma is pursuing breakthrough solutions for devastating neurological disorders with a special emphasis on neurodegenerative diseases. We strive to deliver the right drugs to the right patients by utilizing technology and championing next generation drug development approaches.
The key to discovering and developing better drugs is to understand the disease mechanism. The more we understand, the more effective our therapeutics will be at delivering the right drug to the right patient.
PurMinds’ PurPrecision™ neuromedicine development platform will be used to analyze iPSC-derived neurons from diseased patients and non-neurological healthy controls using multi-omics and integrative computational analyses.
PurMinds champions psychoactive pharmaceutical investigation and believes in the power of psychedelics as a useful tool and catalyst for next generation CNS drug development.
Contact
For any inquiries related to PurMinds NeuroPharma and any of their programs, you can visit their website at https://www.purminds.com/ or send an e-mail to [email protected].
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111794
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis5 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE6 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis5 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Humboldt5 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis3 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III